Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of medical device company Insulet
So what: Revenue jumped 75% to $44.6 million, and loss per share dropped a penny to $0.29. Both results were worse than analysts were expecting, as was revenue guidance of $150 million to $154 million.
Now what: The losses keep mounting and for the full year. Insulet is expecting an operating loss of $39 million to $42 million. I just can't get excited about a company posting losses as far as the eye can see, no matter how fast revenue is growing. I'm going to stay away from this move today, and Insulet can wake me when it actually starts turning a profit.
Interested in more info on Insulet? Add it to your watchlist.
Fool contributor Travis Hoium has no position in any company mentioned. You can follow Travis on Twitter at @FlushDrawFool, check out his personal stock holdings or follow his CAPS picks at TMFFlushDraw.
Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Here's Why Insulet Corporation Jumped Today
Shares soar after management announced a big reimbursement win.
Here's Why Insulet Corporation's Investors Are Pumped
Shares leap after the company reports expectation-smashing results.
Insulet Posts 28% Revenue Growth and Raises 2017 Outlook on Soaring International Sales
The drug delivery specialist’s key metrics continued to move in the right direction in the third quarter.